 <h1>Tev-Tropin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>somatropin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about somatropin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Tev-Tropin.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to somatropin: powder for solution</i></p><p>Other dosage forms:</p><ul><li>powder for solution, solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, somatropin (the active ingredient contained in Tev-Tropin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking somatropin:</p><p>
<i>More common</i>
</p><ul>
<li>Abnormal or decreased touch sensation</li>
<li>bleeding after defecation</li>
<li>bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>changes in skin color</li>
<li>cold flu-like symptoms</li>
<li>cold hands and feet</li>
<li>confusion</li>
<li>constipation</li>
<li>cough or hoarseness</li>
<li>darkened urine</li>
<li>decreased urination</li>
<li>diarrhea</li>
<li>difficult urination</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting or loss of consciousness</li>
<li>fast heartbeat</li>
<li>fast or irregular breathing</li>
<li>feeling unusually cold</li>
<li>fever or chills</li>
<li>full or bloated feeling</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>increase in heart rate</li>
<li>itching or skin rash</li>
<li>joint pain</li>
<li>light-colored stools</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle aching or cramping</li>
<li>muscle pain or stiffness</li>
<li>nausea</li>
<li>pain</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>pressure in the stomach</li>
<li>rapid, shallow breathing</li>
<li>rapid weight gain</li>
<li>rectal bleeding</li>
<li>runny nose</li>
<li>shivering</li>
<li>sneezing</li>
<li>sore mouth or tongue</li>
<li>sore throat</li>
<li>stomach bloating, burning, cramping, or pain</li>
<li>sudden decrease in the amount of urine</li>
<li>sweating</li>
<li>swelling of the abdominal or stomach area</li>
<li>swelling of the eyes or eyelids</li>
<li>swelling or puffiness of the face</li>
<li>swollen joints</li>
<li>thirst</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trouble breathing</li>
<li>trouble sleeping</li>
<li>uncomfortable swelling around the anus</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
<li>vomiting of blood</li>
<li>white patches in the mouth, tongue, or throat</li>
<li>wrinkled skin</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bone or skeletal pain</li>
<li>burning, numbness, pain, or tingling in all fingers except smallest finger</li>
<li>chest pain</li>
<li>depressed mood</li>
<li>dry skin and hair</li>
<li>feeling cold</li>
<li>hair loss</li>
<li>hoarseness or husky voice</li>
<li>slowed heartbeat</li>
<li>swelling of the ankles</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking somatropin:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>changes in vision</li>
<li>cold sweats</li>
<li>coma</li>
<li>cool, pale skin</li>
<li>decrease in the amount of urine</li>
<li>depression</li>
<li>excessive sweating</li>
<li>extreme weakness</li>
<li>flushed, dry skin</li>
<li>frequent urination</li>
<li>fruit-like breath odor</li>
<li>increase in hands and feet size</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>increased volume of pale, diluted urine</li>
<li>nightmares</li>
<li>noisy, rattling breathing</li>
<li>pain in the arms or legs</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>stop in menstruation</li>
<li>swelling of the fingers or hands</li>
<li>troubled breathing at rest</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of somatropin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>breast pain</li>
<li>change in the color, amount, or odor of vaginal discharge</li>
<li>congestion</li>
<li>discoloration of the fingernails or toenails</li>
<li>dryness or soreness of the throat</li>
<li>excess air or gas in the stomach or intestines</li>
<li>frequent urge to defecate</li>
<li>increased sweating</li>
<li>passing gas</li>
<li>sneezing</li>
<li>straining while passing stool</li>
<li>stuffy nose</li>
<li>tender, swollen glands in neck</li>
<li>trouble with swallowing</li>
<li>voice changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Discouragement</li>
<li>feeling sad or empty</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>tiredness</li>
<li>trouble concentrating</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to somatropin: injectable kit, injectable powder for injection, subcutaneous kit, subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were glucose intolerance, fluid retention, injection site reactions, and unmasking of latent central hypothyroidism.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Otitis media (up to 86.4%), surgical procedure (44.6%), peripheral edema (45.4%), edema (25%), flu syndrome (22.9%), ear disorders (17.6%), peripheral swelling (17.5%), leg edema (15%), pain in extremities (19.3%), pain (13.5%), headache (11.4%) </p>
<p><b>Common</b> (1% to 10%): Hematoma, fatigue, flu-like symptoms, asthenia, fatigue, generalized edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Weakness</p>
<p><b>Frequency not reported</b>: Sudden death, pyrexia, ear infection, influenza-like illness, otitis externa, </p>
<p><b>Postmarketing reports</b>: Increased blood alkaline phosphatase level<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): IGF-1 scores above 2 standard deviations (38%), hypothyroidism (16%)</p>
<p><b>Common</b> (1% to 10%): Hypothyroidism</p>
<p><b>Uncommon</b> (0.1% to 1%): Central precocious puberty</p>
<p><b>Frequency not reported</b>: Unmasking of latent central hypothyroidism</p>
<p><b>Postmarketing reports</b>: Decrease in serum thyroxin levels<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Scoliosis was reported as an adverse event in 5 out of 21 children with Noonan Syndrome who were followed for 11 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Arthralgia (37.1%), myalgia (30.4%), scoliosis (23.8%), skeletal pain (11%), back pain (10.9%), arthrosis (10.7%)</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal stiffness, stiffness of extremities, joint stiffness, joint swelling, joint disorder, leg pain, hip pain, progression of preexisting scoliosis,</p>
<p><b>Uncommon</b> (0.1% to 1%): Localized muscle pain, jaw prominence, slipped capital femoral epiphysis </p>
<p><b>Frequency not reported</b>: fracture, joint pain, growth attenuation, interference with growth response, excessive growth of hands or feet, exacerbation of preexisting scoliosis, disproportionate growth of the lower jaw, fracture</p>
<p><b>Postmarketing reports</b>: Legg-Calv√©-Perthes disease<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Impaired fasting glucose (22%), elevated HbA1c (14%), blood glucose increased (13.8%)</p>
<p><b>Common</b> (1% to 10%): Hyperglycemia, hyperlipidemia, glucose tolerance abnormal, fluid retention, hypertriglyceridemia, overt type II diabetes mellitus</p>
<p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus, abnormalities of carbohydrate metabolism (glucose intolerance and high serum HbA1c)</p>
<p><b>Frequency not reported</b>: Glucose intolerance including impaired glucose tolerance/impaired fasting glucose, increased appetite, transient episodes of fasting blood sugars between 100 and 126 mg/dL, transient episodes of fasting blood sugars exceeding 126 mg/dL, increased fasting blood glucose levels, increases in insulin levels, insulin resistance</p>
<p><b>Postmarketing reports</b>: Exacerbation of preexisting diabetes mellitus, diabetic ketoacidosis, diabetic coma<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Paresthesia (17.3%), hypoesthesia (15%) </p>
<p><b>Common</b> (1% to 10%): Hypesthesia, fatigue, carpal tunnel syndrome, Tinel's sign</p>
<p><b>Uncommon</b> (0.1% to 1%): Benign intracranial hypertension, motor problem, seizure<sup>[Ref]</sup></p><p>Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pharyngitis (14.3%), </p>
<p><b>Common</b> (1% to 10%): Nausea, gastroenteritis, gastritis</p>
<p><b>Frequency not reported</b>: Abdominal pain, increased appetite</p>
<p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (12.5%)</p>
<p><b>Common</b> (1% to 10%): ALT increased<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Eosinophilia (12%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Periorbital edema </p>
<p><b>Frequency not reported</b>: Diabetic retinopathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (15.9%), rhinitis (13.5%)</p>
<p><b>Common</b> (1% to 10%): Bronchitis, cough increased, laryngitis, respiratory disorder, dyspnea, sleep apnea</p>
<p><b>Frequency not reported</b>: Influenza, tonsillitis, nasopharyngitis, sinusitis, bronchitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>An IgG antibody has been identified.  No antibodies to the IgE class have been detected.  Growth hormone antibody binding capacities less than 2 mg/L have not led to growth attenuation.  Testing for antibodies should be carried out in any patient failing to respond to treatment.</p>
<p></p>
<p>Primate studies have failed to reveal evidence of histopathological changes due to immune complex formation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anti-rhGH antibodies (24%), infection (non-viral) (13%)</p>
<p><b>Frequency not reported</b>: Antibody formation, anti-periplasmic Escherichia coli peptides (PECP) antibodies<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain</p>
<p><b>Frequency not reported</b>: Injection site reactions/rashes, lipoatrophy, nodules, rash, inflammation, pigmentation, bleeding<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity to solvent (m-cresol/glycerol)</p>
<p><b>Rare</b> (less than 0.1%): Generalized hypersensitivity reactions</p>
<p><b>Postmarketing reports</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Frequency not reported</b>: Cardiac disorders<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Increased sweating, excessive number of cutaneous nevi, acne</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus</p>
<p><b>Rare</b> (less than 0.1%): Rash</p>
<p><b>Frequency not reported</b>: Hair loss, progression of pigmented nevi, eczema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Gynecomastia, breast-related adverse reactions (e.g.  nipple pain, </p>
<p>gynecomastia, breast pain/mass/tenderness/swelling/edema/hypertrophy)</p>
<p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Frequency not reported</b>: Aggressiveness, altered mood<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Glucosuria</p>
<p><b>Frequency not reported</b>: Hematuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very rare</b> (less than 0.01%): Leukemia</p>
<p><b>Frequency not reported</b>: Intracranial tumors including meningiomas, melanocytic nevus<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_3">3. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA. </p><p id="ref_4">4. "Product Information. Serostim (somatropin)." Serono Laboratories Inc, Rockland, MA. </p><p id="ref_5">5. "Product Information. Norditropin Cartridge (somatropin)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Genotropin (somatropin)." Pharmacia and Upjohn, Kalamazoo, MI. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Tev-Tropin (somatropin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: growth hormones</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Genotropin, Norditropin, Omnitrope, Humatrope, ... +8 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to somatropin: injectable kit, injectable powder for injection, subcutaneous kit, subcutaneous powder for injection, subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were glucose intolerance, fluid retention, injection site reactions, and unmasking of latent central hypothyroidism.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Otitis media (up to 86.4%), surgical procedure (44.6%), peripheral edema (45.4%), edema (25%), flu syndrome (22.9%), ear disorders (17.6%), peripheral swelling (17.5%), leg edema (15%), pain in extremities (19.3%), pain (13.5%), headache (11.4%) </p><p><b>Common</b> (1% to 10%): Hematoma, fatigue, flu-like symptoms, asthenia, fatigue, generalized edema</p><p><b>Uncommon</b> (0.1% to 1%): Weakness</p><p><b>Frequency not reported</b>: Sudden death, pyrexia, ear infection, influenza-like illness, otitis externa, </p><p><b>Postmarketing reports</b>: Increased blood alkaline phosphatase level<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Very common</b> (10% or more): IGF-1 scores above 2 standard deviations (38%), hypothyroidism (16%)</p><p><b>Common</b> (1% to 10%): Hypothyroidism</p><p><b>Uncommon</b> (0.1% to 1%): Central precocious puberty</p><p><b>Frequency not reported</b>: Unmasking of latent central hypothyroidism</p><p><b>Postmarketing reports</b>: Decrease in serum thyroxin levels<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Scoliosis was reported as an adverse event in 5 out of 21 children with Noonan Syndrome who were followed for 11 years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Arthralgia (37.1%), myalgia (30.4%), scoliosis (23.8%), skeletal pain (11%), back pain (10.9%), arthrosis (10.7%)</p><p><b>Common</b> (1% to 10%): Musculoskeletal stiffness, stiffness of extremities, joint stiffness, joint swelling, joint disorder, leg pain, hip pain, progression of preexisting scoliosis,</p><p><b>Uncommon</b> (0.1% to 1%): Localized muscle pain, jaw prominence, slipped capital femoral epiphysis </p><p><b>Frequency not reported</b>: fracture, joint pain, growth attenuation, interference with growth response, excessive growth of hands or feet, exacerbation of preexisting scoliosis, disproportionate growth of the lower jaw, fracture</p><p><b>Postmarketing reports</b>: Legg-Calv√©-Perthes disease<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Impaired fasting glucose (22%), elevated HbA1c (14%), blood glucose increased (13.8%)</p><p><b>Common</b> (1% to 10%): Hyperglycemia, hyperlipidemia, glucose tolerance abnormal, fluid retention, hypertriglyceridemia, overt type II diabetes mellitus</p><p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus, abnormalities of carbohydrate metabolism (glucose intolerance and high serum HbA1c)</p><p><b>Frequency not reported</b>: Glucose intolerance including impaired glucose tolerance/impaired fasting glucose, increased appetite, transient episodes of fasting blood sugars between 100 and 126 mg/dL, transient episodes of fasting blood sugars exceeding 126 mg/dL, increased fasting blood glucose levels, increases in insulin levels, insulin resistance</p><p><b>Postmarketing reports</b>: Exacerbation of preexisting diabetes mellitus, diabetic ketoacidosis, diabetic coma<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Paresthesia (17.3%), hypoesthesia (15%) </p><p><b>Common</b> (1% to 10%): Hypesthesia, fatigue, carpal tunnel syndrome, Tinel's sign</p><p><b>Uncommon</b> (0.1% to 1%): Benign intracranial hypertension, motor problem, seizure<sup>[Ref]</sup></p><p>Intracranial hypertension with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pharyngitis (14.3%), </p><p><b>Common</b> (1% to 10%): Nausea, gastroenteritis, gastritis</p><p><b>Frequency not reported</b>: Abdominal pain, increased appetite</p><p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (12.5%)</p><p><b>Common</b> (1% to 10%): ALT increased<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Eosinophilia (12%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Periorbital edema </p><p><b>Frequency not reported</b>: Diabetic retinopathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (15.9%), rhinitis (13.5%)</p><p><b>Common</b> (1% to 10%): Bronchitis, cough increased, laryngitis, respiratory disorder, dyspnea, sleep apnea</p><p><b>Frequency not reported</b>: Influenza, tonsillitis, nasopharyngitis, sinusitis, bronchitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>An IgG antibody has been identified.  No antibodies to the IgE class have been detected.  Growth hormone antibody binding capacities less than 2 mg/L have not led to growth attenuation.  Testing for antibodies should be carried out in any patient failing to respond to treatment.</p><p></p><p>Primate studies have failed to reveal evidence of histopathological changes due to immune complex formation.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anti-rhGH antibodies (24%), infection (non-viral) (13%)</p><p><b>Frequency not reported</b>: Antibody formation, anti-periplasmic Escherichia coli peptides (PECP) antibodies<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain</p><p><b>Frequency not reported</b>: Injection site reactions/rashes, lipoatrophy, nodules, rash, inflammation, pigmentation, bleeding<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity to solvent (m-cresol/glycerol)</p><p><b>Rare</b> (less than 0.1%): Generalized hypersensitivity reactions</p><p><b>Postmarketing reports</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Frequency not reported</b>: Cardiac disorders<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Increased sweating, excessive number of cutaneous nevi, acne</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus</p><p><b>Rare</b> (less than 0.1%): Rash</p><p><b>Frequency not reported</b>: Hair loss, progression of pigmented nevi, eczema<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Gynecomastia, breast-related adverse reactions (e.g.  nipple pain, </p><p>gynecomastia, breast pain/mass/tenderness/swelling/edema/hypertrophy)</p><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Frequency not reported</b>: Aggressiveness, altered mood<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Glucosuria</p><p><b>Frequency not reported</b>: Hematuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very rare</b> (less than 0.01%): Leukemia</p><p><b>Frequency not reported</b>: Intracranial tumors including meningiomas, melanocytic nevus<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN. </p><p id="ref_3">3. "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA. </p><p id="ref_4">4. "Product Information. Serostim (somatropin)." Serono Laboratories Inc, Rockland, MA. </p><p id="ref_5">5. "Product Information. Norditropin Cartridge (somatropin)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Genotropin (somatropin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><h2>More about Tev-Tropin (somatropin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: growth hormones</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>